US Regulator Orders Vision Loss Warnings for Popular Weight-Loss Medications

The United States Food and Drug Administration has mandated updated safety labels for all GLP-1 receptor agonist medications, following evaluations that linked the drugs to a potential risk of a rare eye condition. The regulatory agency announced the decision after reviewing data on treatments widely prescribed for weight management and type 2 diabetes.

The targeted drug class includes popular pharmaceutical products such as Novo Nordisk's Ozempic and Wegovy, alongside Eli Lilly's Mounjaro and Zepbound. Under the new FDA requirements, product labeling must highlight the potential risk of non-arteritic anterior ischaemic optic neuropathy, commonly known as NAION. The medical condition causes sudden, painless loss of vision in one eye, which can lead to permanent visual impairment.

The regulatory decision follows an extensive agency assessment that evaluated 126 clinical trials involving more than 134,000 patients. FDA officials also analyzed real-world clinical data and published observational research during their review. While the agency acknowledged existing limitations in the available scientific evidence, it determined that the overall data supported issuing mandatory warnings across all medications in the GLP-1 class.

The European Medicines Agency had previously examined safety data regarding semaglutide, the active ingredient in Ozempic and Wegovy. The European regulator subsequently classified NAION as a very rare side effect of the substance, estimating its occurrence at up to one in 10,000 patients. The updated American requirements extend similar label warnings across all competing drugs within the broader GLP-1 category.

Written by Christiane Hofreiter christiane.hofreiter@alpineweekly.com